Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THPy vs THP as first-line therapy for advanced HER2-positive breast cancer
ChiCTR2500101511Phase 4Recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pyrotinib, trastuzumab, pertuzumab and trastuzumab rezetecan in breast cancer (2 arms), sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: progression-free survival. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500101511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101511.